Added benefit of lisdexamfetamine is not proven
Tuesday, September 3, 2013 - 09:50
in Health & Medicine
A short-term study on the new ADHD drug lisdexamfetamine was unsuitable for several reasons, mainly because the treatment was not conducted as part of a comprehensive treatment program, and no added benefit of the drug can be derived.